Join Resistell at OBERON to see our Rapid AST solution at Pitch Night 2019, where 10 of Switzerland’s most promising young HealthTech startups will pitch their ideas alongside their counterparts from North America, including some of the Boston area’s favorite early Life Sciences startups.
We would like to thank the colleagues from the Uppsala Antibiotic Centre for the invitation to an excellent Symposium on Rapid ASTs. We are impressed by the quality of the event, participants and the discussions and honoured to be an invited speaker.
Danuta selected as top four up-and-coming entrepreneurs who made the best pitch at the annual Startup Champions Seed Night. Watch us on CNN Money and see how we will take our startup to the next level.
We invite you to meet us in Amsterdam at ECCMID 2019 (13 - 16 April 2019) and learn more about our rapid AST approach, see the product and discuss the future cooperations. Meet us any time at the booth 1.107!
“This process is one of the most rapid methods in this review and can be used to develop quantitative anti-biograms”, Puttaswamy et al., 2018, Archives of Clinical Microbiology, 9:3, 83 https://doi.org/10.4172/1989-8436.100083
Well done to all our colleagues from CHUV Hospital, recently listed in the top 10 best hospitals in the world. Resistell is proud to develop the rapid AST with the support of CHUV Hospital. Thank you and congratulations!
Resistell was selected as one of ten new startups have been selected for Venture Leaders Life Sciences 2019. Chosen from among the most-promising life sciences startups in Switzerland, the team will embark on a packed, week-long roadshow in Boston. The startups will also pitch at the Startup Champions Seed Night event in Lausanne on 11 April.
We thank everyone who visited our scientific presentation in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). We are looking forward to all new future partnerships and collaborations!
Resistell has closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test.
Im Rahmen des ersten Swiss Diagnostics Start-Up Day 2017 an der Fachhochschule Nordwestschweiz präsentierten sechs Start-Ups aus der Biotechnologie und Diagnostik ihre Geschäftsideen einer Expertenjury.